Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2026 18:25 ET | Source: Galapagos NV

Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines New partnership structure would achieve meaningfully improved financial terms...
March 23, 2026 16:30 ET | Source: Vor Biopharma

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and...
March 23, 2026 16:05 ET | Source: Abivax

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis...
March 23, 2026 16:05 ET | Source: Sutro Biopharma, Inc.

Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned...
March 23, 2026 16:05 ET | Source: Surrozen, Inc.

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
March 23, 2026 16:01 ET | Source: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential...
March 23, 2026 13:17 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics anuncia el resultado positivo de la reunión de cierre de la fase 2 con la FDA de EE. UU. sobre el diseño de un ensayo de fase 3 del VCN-01 para el adenocarcinoma ductal pancreático metastásico

– El éxito de la reunión con la FDA permite avanzar hacia el ensayo clínico de fase 3 propuesto del VCN-01 en combinación con gemcitabina/nab-paclitaxel para el tratamiento de primera línea del ACDP...
March 23, 2026 13:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics invitée à présenter lors des prochaines conférences investisseurs

Nantes, France, 23 mars 2026 – 18h00 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE), une société de biotechnologie au stade clinique développant des thérapies first-in-class en...
March 23, 2026 13:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics to Present at Upcoming Investor Conferences

OSE Immunotherapeutics to Present at Upcoming Investor Conferences
March 23, 2026 12:54 ET | Source: Novonesis (Novozymes A/S)

Resolutions from the Annual General Meeting 2026

Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025Approval of distribution of profit...